NYSE:TDOC   Teladoc Health, Inc.
Teladoc Health's shares skyrocketed nearly 140% last year. So far in 2021, though, the stock is down close to 30%.
The average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives TDOC stock a score of 29 out of a possible 100. That rank is mainly influenced by a short-term technical score of 10. TDOC's rank also includes a long-term technical score of 13. The fundamental score for TDOC is 65.
In addition to the average rating from Wall Street analysts, TDOC stock has a mean target price of $208.88. This means analysts expect the stock to gain 48.25% over the next 12 months.

I think TDOC is absolutely here to stay.
Telehealth will grow, and beyond Telehealth, virtual care in general.
Chronic disease management, I think it was a good acquisition for Teladoc. I thought it brought a good platform into its lineup, and there's a great opportunity for cross-selling there.
-
After a long battle to hold its price since late February TDOC had finally formed a falling wedge on the daily chart.
It’s starting to look very clean here for a continuation up.
A clean break on the falling wedge.
RSI breaking above 50
& the MACD curling
I suggest keeping this on your watchlist.
- Factor Four

Thông báo miễn trừ trách nhiệm

Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.